|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
10
|
|
pubmed:dateCreated |
2011-5-17
|
|
pubmed:abstractText |
To facilitate development of innovative immunotherapy approaches, especially for treatment concepts exploiting the potential benefits of personalized therapy, there is a need to develop and validate tools to identify patients who can benefit from immunotherapy. Despite substantial effort, we do not yet know which parameters of antitumor immunity to measure and which assays are optimal for those measurements.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
pubmed-author:BrittenCedrik MCM,
pubmed-author:ButterfieldLisa HLH,
pubmed-author:DhodapkarMadhav VMV,
pubmed-author:DisisMary LML,
pubmed-author:FoxBernard ABA,
pubmed-author:HåkanssonLeifL,
pubmed-author:JanetzkiSylviaS,
pubmed-author:KawakamiYutakaY,
pubmed-author:KhleifSamirS,
pubmed-author:KleenThomas-OliverTO,
pubmed-author:LeePeter PPP,
pubmed-author:MaccalliCristinaC,
pubmed-author:MaeckerHolden THT,
pubmed-author:MainoVernon CVC,
pubmed-author:MaioMicheleM,
pubmed-author:MalyguineAnatoliA,
pubmed-author:MarincolaFrancescoF,
pubmed-author:MasucciGiuseppeG,
pubmed-author:PaluckaA KarolinaAK,
pubmed-author:PawelecGrahamG,
pubmed-author:PotterDouglas MDM,
pubmed-author:RivoltiniLiciaL,
pubmed-author:SalazarLupe GLG,
pubmed-author:SchendelDolores JDJ,
pubmed-author:SlingluffCraig LCLJr,
pubmed-author:SongWenruW,
pubmed-author:StroncekDavid FDF,
pubmed-author:TaharaHideakiH,
pubmed-author:ThurinMagdalenaM,
pubmed-author:TrinchieriGiorgioG,
pubmed-author:WhitesideTheresa LTL,
pubmed-author:WiggintonJon MJM,
pubmed-author:van Der BurgSjoerd HSH
|
|
pubmed:copyrightInfo |
©2011 AACR.
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
17
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
3064-76
|
|
pubmed:meshHeading |
pubmed-meshheading:21558394-Consensus Development Conferences as Topic,
pubmed-meshheading:21558394-Health Planning Guidelines,
pubmed-meshheading:21558394-Humans,
pubmed-meshheading:21558394-Immunotherapy,
pubmed-meshheading:21558394-International Agencies,
pubmed-meshheading:21558394-Medical Oncology,
pubmed-meshheading:21558394-National Cancer Institute (U.S.),
pubmed-meshheading:21558394-Neoplasms,
pubmed-meshheading:21558394-Practice Guidelines as Topic,
pubmed-meshheading:21558394-Societies, Medical,
pubmed-meshheading:21558394-Tumor Markers, Biological,
pubmed-meshheading:21558394-United States,
pubmed-meshheading:21558394-United States Food and Drug Administration
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers.
|
|
pubmed:affiliation |
Department of Medicine, University of Pittsburgh, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, Pennsylvania 15213, USA.
|
|
pubmed:publicationType |
Journal Article,
Review,
Research Support, N.I.H., Extramural
|
